Aluminium absorption and antacid therapy in infancy

Area of Science:

• Pediatric Medicine
• Clinical Pharmacology
• Toxicology

Background:

• Antacid therapy is commonly used for infant feeding and settling problems.
• Aluminum absorption from antacids in infants has not been well-established.
• Concerns exist regarding potential aluminum toxicity, especially in infants with impaired renal function.

Purpose of the Study:

• To investigate aluminum absorption in infants undergoing antacid therapy.
• To compare aluminum levels in infants receiving antacids versus a control group.
• To assess the potential risk of aluminum toxicity in infants using antacids.

Main Methods:

• Prospective study conducted over 11 weeks at Torrens House.
• Inclusion of infants receiving antacid therapy and age-matched controls.
• Measurement of plasma and urine aluminum levels using standardized laboratory techniques.

Main Results:

• Infants receiving antacids showed significantly higher plasma (3.3 +/- 2.2 mumol/L) and urine (25.1 +/- 27.6 mumol/L) aluminum levels compared to controls (plasma 1.5 +/- 1.5 mumol/L, urine 1.1 +/- 1.8 mumol/L).
• Fifty percent of infants on antacids exhibited plasma aluminum levels associated with toxicity in renal failure patients.
• Significant statistical differences were observed (P < 0.01 for plasma, P < 0.004 for urine).

Conclusions:

• Infants demonstrably absorb aluminum from antacid therapy.
• Variable absorption suggests a potential risk of aluminum toxicity in susceptible infants.
• Routine monitoring of plasma aluminum levels is recommended for infants receiving antacids to mitigate toxicity risks.